MedTrace Logo

Health Improvements by Understanding the Determinants of Residual Risk in Coronary Artery Disease and New Targets for Prevention and Treatment

NCT06601153 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 961

Last updated 2024-09-19

No results posted yet for this study

Summary

Current medical treatments, in patients with stable coronary artery disease (CAD), mainly target established risk factors and are able to reduce morbidity and mortality but still leave a substantial residual risk of coronary artery disease progression and events. The main hypothesis of this study is that metabolic derangement, including pre-diabetes, elevated levels of triglycerides, low levels and functionality of high-density lipoprotein cholesterol, often associated with a chronic inflammatory state, is a currently unrecognized and undertreated conditon which could be the most relevant determinant of residual risk.

The goal of HURRICANE observational study is to discover specific individual genetic/molecular profiles subtending emerging cardiometabolic and vascular risk patterns and associating with a more severe and progressive coronary artery disease. We will thus develop and preliminary validate new predictive models for the recognition of high-risk patients and explore possible new targets for individualized preventive treatment.

The severity, extent and progression of coronary plaques will be assessed by qualitative and quantitative analysis of cardiac computed tomography (CCT) performed in retrospective and prospective cohorts of patients with stable coronary disease.

Conditions

  • Coronary Arterial Disease (CAD)

Interventions

DIAGNOSTIC_TEST

Cardiac CT

Cardiac CT to characterize coronary atherosclerosis

Sponsors & Collaborators

  • CNR Institute of Clinical Physiology, Pisa, Italy

    collaborator UNKNOWN

  • IRCCS SYNLAB SDN, Naples, Italy

    collaborator UNKNOWN

  • Fondazione Toscana Gabriele Monasterio

    lead OTHER

Principal Investigators

  • Danilo Neglia, MD, PhD · Fondazione Toscana Gabriele Monasterio

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-07
Primary Completion
2025-10-31
Completion
2025-12-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06601153 on ClinicalTrials.gov